Combination of pembrolizumab and radiotherapy induces systemic antitumor immune responses in immunologically cold non-small cell lung cancer.

Nat Cancer · 2025 · PMC12559004 · PMID 40696153

Europe PMC DOI

hedged sentence

0.0840

closest p · 1.7× alpha

0.0840

boldest claim

The sentences

showed a trendP = 0.084so close (0.05 < p ≤ 0.1)

Similarly, participants with PDL1-null tumors showed a trend toward longer OS in the SBRT arm compared with the control arm (median OS: 7.21 versus 6.05 months; log-rank test, P = 0.084) (Extended Data Fig. 8b ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.